MedTrace Logo

the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections.

NCT03134495 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 290286

Last updated 2017-05-01

No results posted yet for this study

Summary

Pharmacological treatment of physiologic Gastro-esophageal Reflux disease (GERD) is excessive in France, as 65%-85% of children below 11 years are being treated, frequently with Proton Pump Inhibitors (PPIs) PPI have been associated, in adults, with an increase of infection rate but data in pediatry are scarce, especially in community medecine. Recently a study conducted in England brought up controversial results suggesting that the use of PPIs can be associated with a reduced risk of community acquired pneumonia.

Our study was aimed to assess, on a population-based database, the association between PPI prescription and community infections in children of 11 years or under.

Conditions

  • Community Infections

Interventions

OTHER

all children with at least one prescription of PPI

all children with at least one prescription of PPI

OTHER

all children with no prescription of PPI

all children with no prescription of PPI

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Eligibility

Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-03-31
Completion
2017-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03134495 on ClinicalTrials.gov